{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T15:14:49Z","timestamp":1778685289651,"version":"3.51.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T00:00:00Z","timestamp":1776470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T00:00:00Z","timestamp":1776470400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006396","name":"Alexion Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006396","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pain Ther"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s40122-026-00837-8","type":"journal-article","created":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T03:33:04Z","timestamp":1776483184000},"page":"803-815","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of Selumetinib on Long-Term Pain Medication Utilization in Pediatric Patients: A Retrospective US Claims Database Study"],"prefix":"10.1007","volume":"15","author":[{"given":"Genevieve","family":"Lyons","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theresa","family":"Dettling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alyssa","family":"Bowling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashwin","family":"Anand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Sicilia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wouter","family":"van der Pluijm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Guikema","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Meade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,18]]},"reference":[{"key":"837_CR1","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/S1474-4422(14)70063-8","volume":"13","author":"AC Hirbe","year":"2014","unstructured":"Hirbe AC, Gutmann DH. Neurofibromatosis type 1: a multidisciplinary approach to care. Lancet Neurol. 2014;13:834\u201343.","journal-title":"Lancet Neurol"},{"key":"837_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-020-1310-3","volume":"15","author":"C Bergqvist","year":"2020","unstructured":"Bergqvist C, Servy A, Valeyrie-Allanore L, Ferkal S, Combemale P, Wolkenstein P. Neurofibromatosis 1 - French national guidelines based on an extensive literature review since 1966. Orphanet J Rare Dis. 2020;15:37.","journal-title":"Orphanet J Rare Dis"},{"key":"837_CR3","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/ajmg.a.33139","volume":"152a","author":"DG Evans","year":"2010","unstructured":"Evans DG, Howard E, Giblin C, et al. Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet A. 2010;152a:327\u201332.","journal-title":"Am J Med Genet A"},{"key":"837_CR4","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1001\/archderm.141.1.71","volume":"141","author":"M Lammert","year":"2005","unstructured":"Lammert M, Friedman JM, Kluwe L, Mautner VF. Prevalence of neurofibromatosis 1 in German children at elementary school enrollment. Arch Dermatol. 2005;141:71\u20134.","journal-title":"Arch Dermatol"},{"key":"837_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-7-75","volume":"7","author":"R Nguyen","year":"2012","unstructured":"Nguyen R, Dombi E, Widemann BC, et al. Growth dynamics of plexiform neurofibromas: a retrospective cohort study of 201 patients with neurofibromatosis 1. Orphanet J Rare Dis. 2012;7:75.","journal-title":"Orphanet J Rare Dis"},{"key":"837_CR6","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1093\/neuonc\/nov200","volume":"18","author":"JO Blakeley","year":"2016","unstructured":"Blakeley JO, Plotkin SR. Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis. Neuro Oncol. 2016;18:624\u201338.","journal-title":"Neuro Oncol"},{"key":"837_CR7","first-page":"1573","volume":"62","author":"RE Ferner","year":"2002","unstructured":"Ferner RE, Gutmann DH. International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis. Cancer Res. 2002;62:1573\u20137.","journal-title":"Cancer Res"},{"key":"837_CR8","doi-asserted-by":"publisher","first-page":"205031211982968","DOI":"10.1177\/2050312119829680","volume":"7","author":"A Heaney","year":"2019","unstructured":"Heaney A, Wilburn J, Langmead S, et al. A qualitative study of the impact of plexiform neurofibromas on need fulfilment in adults with neurofibromatosis type 1. SAGE Open Med. 2019;7:2050312119829680.","journal-title":"SAGE Open Med"},{"key":"837_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s12887-021-02530-5","volume":"21","author":"F Baldo","year":"2021","unstructured":"Baldo F, Magnolato A, Barbi E, Bruno I. Selumetinib side effects in children treated for plexiform neurofibromas: first case reports of peripheral edema and hair color change. BMC Pediatr. 2021;21:67.","journal-title":"BMC Pediatr"},{"key":"837_CR10","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1093\/neuonc\/noy067","volume":"20","author":"AM Gross","year":"2018","unstructured":"Gross AM, Singh G, Akshintala S, et al. Association of plexiform neurofibroma volume changes and development of clinical morbidities in neurofibromatosis 1. Neuro Oncol. 2018;20:1643\u201351.","journal-title":"Neuro Oncol"},{"key":"837_CR11","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1634\/theoncologist.2013-0328","volume":"19","author":"M Farid","year":"2014","unstructured":"Farid M, Demicco EG, Garcia R, et al. Malignant peripheral nerve sheath tumors. Oncologist. 2014;19:193\u2013201.","journal-title":"Oncologist"},{"key":"837_CR12","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1007\/s10072-021-05361-5","volume":"43","author":"I Iheanacho","year":"2022","unstructured":"Iheanacho I, Yoo HK, Yang X, Dodman S, Hughes R, Amin S. Epidemiological and clinical burden associated with plexiform neurofibromas in pediatric neurofibromatosis type-1 (NF-1): a systematic literature review. Neurol Sci. 2022;43:1281\u201393.","journal-title":"Neurol Sci"},{"key":"837_CR13","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1200\/JCO.24.01034","volume":"43","author":"CL Moertel","year":"2025","unstructured":"Moertel CL, Hirbe AC, Shuhaiber HH, et al. ReNeu: a pivotal, phase IIb trial of mirdametinib in adults and children with symptomatic neurofibromatosis type 1-associated plexiform neurofibroma. J Clin Oncol. 2025;43:716\u201329.","journal-title":"J Clin Oncol"},{"key":"837_CR14","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1007\/s00381-022-05513-8","volume":"38","author":"X Yang","year":"2022","unstructured":"Yang X, Yoo HK, Amin S, et al. Clinical and humanistic burden among pediatric patients with neurofibromatosis type 1 and plexiform neurofibroma in the USA. Childs Nerv Syst. 2022;38:1513\u201322.","journal-title":"Childs Nerv Syst"},{"key":"837_CR15","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJMoa1912735","volume":"382","author":"AM Gross","year":"2020","unstructured":"Gross AM, Wolters PL, Dombi E, et al. Selumetinib in children with inoperable plexiform neurofibromas. N Engl J Med. 2020;382:1430\u201342.","journal-title":"N Engl J Med"},{"key":"837_CR16","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1007\/s40120-022-00365-5","volume":"11","author":"X Yang","year":"2022","unstructured":"Yang X, Yoo HK, Amin S, et al. Burden among caregivers of pediatric patients with neurofibromatosis type 1 (NF1) and plexiform neurofibroma (PN) in the United States: a cross-sectional study. Neurol Ther. 2022;11:1221\u201333.","journal-title":"Neurol Ther"},{"key":"837_CR17","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1002\/ajmg.a.37123","volume":"167A","author":"PL Wolters","year":"2015","unstructured":"Wolters PL, Burns KM, Martin S, et al. Pain interference in youth with neurofibromatosis type 1 and plexiform neurofibromas and relation to disease severity, social-emotional functioning, and quality of life. Am J Med Genet A. 2015;167A:2103\u201313.","journal-title":"Am J Med Genet A"},{"key":"837_CR18","unstructured":"AstraZeneca. Koselugo (selumetinib) approved in US for paediatric patients with neurofibromatosis type 1 plexiform neurofibromas [Internet]. Cambridge: AstraZeneca; [cited 2025 Sep 22]. https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2020\/koselugo-selumetinib-approved-in-us-for-paediatric-patients-with-neurofibromatosis-type-1-plexiform-neurofibromas.html#."},{"key":"837_CR19","unstructured":"U.S. Food and Drug Administration. FDA approves selumetinib for pediatric patients 1 year of age and older with neurofibromatosis type 1 with symptomatic, inoperable plexiform neurofibromas [Internet]. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-selumetinib-pediatric-patients-1-year-age-and-older-neurofibromatosis-type-1."},{"key":"837_CR20","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1016\/S0140-6736(25)00986-9","volume":"405","author":"AP Chen","year":"2025","unstructured":"Chen AP, Coyne GO, Wolters PL, et al. Efficacy and safety of selumetinib in adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas (KOMET): a multicentre, international, randomised, placebo-controlled, parallel, double-blind, phase 3 study. Lancet. 2025;405:2217\u201330.","journal-title":"Lancet"},{"key":"837_CR21","unstructured":"AstraZeneca. Selumetinib approved in the US for adults with neurofibromatosis type 1 [Internet]. Cambridge: AstraZeneca; 2025 [Nov 20]. https:\/\/www.astrazeneca-us.com\/media\/press-releases\/2025\/KOSELUGO-selumetinib-approved-in-the-US-for-adults-with-neurofibromatosis-type-1.html."},{"key":"837_CR22","first-page":"S358","volume":"27","author":"G Lyons","year":"2026","unstructured":"Lyons G, Meade J, Dettling T, Erdmann M, Guikema B, Adeyemi A. Treatment patterns and change in pain medication utilization in pediatric patients treated with selumetinib: a US claims database analysis. Clin Ther. 2026;27:S358.","journal-title":"Clin Ther"},{"key":"837_CR23","first-page":"35","volume":"7","author":"AO Iuga","year":"2014","unstructured":"Iuga AO, McGuire MJ. Adherence and health care costs. Risk Manag Healthc Policy. 2014;7:35\u201344.","journal-title":"Risk Manag Healthc Policy"},{"key":"837_CR24","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1542\/peds.2013-1451","volume":"132","author":"ME McGrady","year":"2013","unstructured":"McGrady ME, Hommel KA. Medication adherence and health care utilization in pediatric chronic illness: a systematic review. Pediatrics. 2013;132:730\u201340.","journal-title":"Pediatrics"},{"key":"837_CR25","doi-asserted-by":"publisher","first-page":"155","DOI":"10.5001\/omj.2011.38","volume":"26","author":"B Jimmy","year":"2011","unstructured":"Jimmy B, Jose J. Patient medication adherence: measures in daily practice. Oman Med J. 2011;26:155\u20139.","journal-title":"Oman Med J"},{"key":"837_CR26","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1136\/rapm-00115550-200805000-00002","volume":"33","author":"SP Cohen","year":"2008","unstructured":"Cohen SP, Christo PJ, Wang S, et al. The effect of opioid dose and treatment duration on the perception of a painful standardized clinical stimulus. Reg Anesth Pain Med. 2008;33:199\u2013206.","journal-title":"Reg Anesth Pain Med"},{"key":"837_CR27","doi-asserted-by":"publisher","first-page":"515","DOI":"10.2147\/TCRM.S79409","volume":"11","author":"F Coluzzi","year":"2015","unstructured":"Coluzzi F, Pergolizzi J, Raffa RB, Mattia C. The unsolved case of \u201cbone-impairing analgesics\u201d: the endocrine effects of opioids on bone metabolism. Ther Clin Risk Manag. 2015;11:515\u201323.","journal-title":"Ther Clin Risk Manag"},{"key":"837_CR28","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1200\/JCO.1997.15.1.110","volume":"15","author":"G Liu","year":"1997","unstructured":"Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol. 1997;15:110\u20135.","journal-title":"J Clin Oncol"},{"key":"837_CR29","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/S0959-8049(01)00371-9","volume":"38","author":"MM Borner","year":"2002","unstructured":"Borner MM, Schoffski P, de Wit R, et al. Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur J Cancer. 2002;38:349\u201358.","journal-title":"Eur J Cancer"},{"key":"837_CR30","first-page":"56","volume":"59","author":"K Ruddy","year":"2009","unstructured":"Ruddy K, Mayer E, Partridge A. Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin. 2009;59:56\u201366.","journal-title":"CA Cancer J Clin"},{"key":"837_CR31","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1093\/jnci\/94.9.652","volume":"94","author":"AH Partridge","year":"2002","unstructured":"Partridge AH, Avorn J, Wang PS, Winer EP. Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst. 2002;94:652\u201361.","journal-title":"J Natl Cancer Inst"},{"key":"837_CR32","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1634\/theoncologist.2015-0405","volume":"21","author":"JA Greer","year":"2016","unstructured":"Greer JA, Amoyal N, Nisotel L, et al. A systematic review of adherence to oral antineoplastic therapies. Oncologist. 2016;21:354\u201376.","journal-title":"Oncologist"},{"key":"837_CR33","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1310\/hpj5202-124","volume":"52","author":"S El-Rachidi","year":"2017","unstructured":"El-Rachidi S, LaRochelle JM, Morgan JA. Pharmacists and pediatric medication adherence: bridging the gap. Hosp Pharm. 2017;52:124\u201331.","journal-title":"Hosp Pharm"},{"key":"837_CR34","unstructured":"Administration. USFaD. Neurontin prescribing information 2020 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/020235s079,020882s060,021129s059lbl.pdf."}],"container-title":["Pain and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40122-026-00837-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40122-026-00837-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40122-026-00837-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T14:34:57Z","timestamp":1778682897000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40122-026-00837-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,18]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["837"],"URL":"https:\/\/doi.org\/10.1007\/s40122-026-00837-8","relation":{},"ISSN":["2193-8237","2193-651X"],"issn-type":[{"value":"2193-8237","type":"print"},{"value":"2193-651X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,18]]},"assertion":[{"value":"16 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Alyssa Bowling, Genevieve Lyons, and Theresa Dettling are employees of Alexion, AstraZeneca Rare Disease, and may own stock or stock options in Alexion, AstraZeneca Rare Disease. Ashwin Anand, Michael Sicilia, and Wouter van der Pluijm are employees of Forian Inc. and may hold stock or stock options in Forian Inc. Benjamin Guikema was an employee of Alexion, AstraZeneca Rare Disease at the time of study, and may own stock or stock options in Alexion, AstraZeneca Rare Disease. Benjamin Guikema is presently an employee of KalVista Pharmaceuticals, Inc., and may own stock or stock options in KalVista Pharmaceuticals, Inc. Julia Meade has received consulting fees from Alexion, AstraZeneca Rare Disease, HMP Omnimedia, Revhealth, and Distance Learning Network and has received payment for travel from The Children\u2019s Oncology Group.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This retrospective observational study utilizes data products licensed from Forian Inc. that include patient-level data de-identified in compliance with the federal privacy and security rules of the Health Insurance Portability and Accountability Act of 1996, as amended (\u201cHIPAA\u201d), including by the Health Information Technology for Economic and Clinical Health Act and any implementing regulations issued by the U.S. Department of Health and Human Services pursuant thereto, and the regulations published thereunder at 45 CFR Parts 160, 162, and 164, as may be amended from time to time, known as the Standards for Privacy of Individually Identifiable Health Information (\u201cPrivacy Rule\u201d) and the Security Standards (the \u201cSecurity Rule\u201d, and together with the Privacy Rule, the \u201cHIPAA Regulations\u201d), as certified by the determination of a qualified expert in accordance with Section \u00a7164.514(b)(1) of the Privacy Rule. At the time of the analysis yielding the study, Forian\u2019s CHRONOS data product included healthcare claims data from over 300 million de-identified patients receiving care in the US between 2017 and 2023. This study utilizes only de-identified patient-level data and was therefore exempt from Institutional Review Board approval.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}